CTVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Corteva Inc (CTVA) is not a strong buy for a beginner investor with a long-term horizon at this moment. The stock is experiencing a downward trend in price, and while the company has some positive catalysts such as upcoming spin-offs and improved gross margins, the financial performance and mixed analyst ratings suggest caution. Additionally, there are no strong trading signals or significant insider or hedge fund activity to support a buy decision.
The stock is showing a bearish trend with a negatively expanding MACD histogram (-0.145) and an RSI of 38.912, which is close to oversold but still neutral. The price is below the pivot level (78.136) and nearing the first support level (76.02). Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the overall technical indicators suggest caution.
Upcoming spin-off of the Seed and Crop Chemicals business, which could unlock shareholder value.
Improved gross margin (38.29, up 15.58% YoY).
Analyst price targets range from $75 to $89, with some firms maintaining Outperform ratings.
Recent price decline (-1.81% in regular market, -0.76% post-market).
Revenue dropped by -1.71% YoY in Q4
Mixed analyst ratings, with some downgrades citing valuation concerns and execution risks for the planned spin-off.
No significant insider or hedge fund activity to indicate confidence in the stock.
In Q4 2025, revenue dropped to $3.91 billion (-1.71% YoY), while net income improved significantly to -$552 million (+1246.34% YoY). EPS increased to -0.82 (+1266.67% YoY), and gross margin improved to 38.29 (+15.58% YoY). Despite some positive trends, the revenue decline and negative net income remain concerns.
Analyst ratings are mixed, with price targets ranging from $75 to $89. Positive ratings highlight the potential benefits of the spin-off and improved EBITDA growth, while negative ratings cite valuation concerns and execution risks for the planned separation of business units.
